|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Technology Commercialisation: Developing Biotech Start-Ups | ||||||||||||||||
| February 21, 2001 | ||||||||||||||||
|
SMi Pharma, The Hatton, London 21st - 22nd May 2001 plus morning workshop 23rd May Day One – Monday May 21st 2001 8.30 Registration & Coffee CHAIRMAN'S OPENING PRESENTATION 9.10 Trends and opportunities: an overview Financing trends in the biotech sector Creating opportunities in life sciences Collaborations: the lifeblood of biotechs Dimitri F Dimitriou, Senior Director, Worldwide Business Development, GlaxoSmithKline REVIEWING THE TECHNICAL AND COMMERCIAL ASSESSMENT OF DEVELOPMENT STAGE TECHNOLOGIES 9.40 Focusing on new approaches Strategic needs of emerging companies: from set up to launch Assessing opportunities and developing strategies for seeking optimum funding Assessing scientific innovation vs generating financial forecasts: critique valuation methods Developing the need for a technology valuation scoring system Understanding the individual needs of various stakeholders Developing communication strategies targeted to the different needs of stakeholders Adam Raman, Director, Strategy Development, PHASE II International IS YOUR MOLECULE READY TO MARKET OR PARTNER? 10.20 Incorporating marketing objectives into clinical development Historically, the pharma and biotech industries have focused on the NDA, not the market, when designing clinical programs This myopia often resulted in unnecessary marketing limitations due to an unnecessarily restrictive label This presentation will discuss new strategies for evaluating drug candidates and their markets in order to realise a molecule’s full potential either in the market or in a partnering deal One or more case studies will be presented Mark A King, Managing Director, Kendall Strategies 11.00 Morning Coffee COMMERCIALISING A LEAD CANCER PRODUCT 11.20 Case study: Antigenics Developing an integrated infrastructure to develop and commercialise Oncophage® Expanding the clinical development programme Building a sales force prior to commercialisation Creating value through prudent funding strategies Dr Elma S Hawkins, Vice Chairman, Antigenics TECHNOLOGY TRANSFER 12.00 The commercialisation process Why transfer technology from universities? Recognising the commercial implications of academic discoveries What are the stages of technology transfer and commercialisation? What are the options for technology commercialisation from academia? Established companies, start-ups or spin-offs? Bringing science and commercial groups together Glynn Edwards, Chief Executive Officer, Antisoma 12.40 Networking Lunch COMMERCIALISING TECHNOLOGY FROM ACADEMIA 2.00 Striding the academic-industrial interface: a personal view An industrialist links with academics An industrialist joins an academic spin-out From spin-out to buy-out From buy-out to acquisition to academic chair Start-up / spin-out of a service business Spin-out of a R&D business Prof Howard Stevens, Pfizer Professor of Exploratory Drug Delivery, Department of Pharmaceutical Sciences, University of Strathclyde, UK FROM ACADEMIA TO BIOTECH: A SUCCESS STORY 2.40 Case study: Acambis A brief history of Acambis From university to biotech: the stages of company development and technology commercialisation Technology platforms for new vaccines Commercialising the technology Strengthening the financial position through alliances Focusing the portfolio Maintaining a strategy for constant new product opportunities Dr John Brown, Chief Executive Officer, Acambis 3.20 Afternoon Tea TECHNOLOGY TRANSFER: THE HUMAN FACTOR 3.40 From innovation to commercialisation Understanding the stages and some of the issues involved Working toward speeding up the process from innovation to commercialisation What human skills are required for successful technology transfer? Finding the right teams Integrating the scientific and commercial teams Planning for success, some good and bad examples Cynthia Larbey, Managing Director, People in Health FROM THE LABORATORY TO THE MARKET-PLACE 4.20 The challenges of commercialising science Historical perspective: what motivates scientists? The current situation: how do scientists link up with business? Geographical comparisons: US vs European culture Venture capital, biotechnology companies, big Pharma – an exploration of their different roles The future: where will we be in five years time? Dr Peter MacLennan, Director of Business Development, Pharma-Transfer 5.00 Chairman’s Closing Remarks and Close of Day One 5.10 Networking Drinks Reception Day Two – Tuesday May 22nd 2001 8.30 Re-registration and Coffee 9.00 Chairman's Opening Remarks Dr Nigel Parker, Chief Executive Officer, Ark Therapeutics EARLY STAGE FUNDING 9.10 Raising finance Funding options for early stage biotech businesses The importance of the right partner for the biotech start-up Identifying and evaluating potential partners Access to capital and the effect on IP protection How can the biotech start-up present themselves to increase their chances of funding and commercialisation? Antony Ross, Director, Healthcare, 3i Group RAISING FINANCIAL SUPPORT FOR COMMERCIALISATION 9.40 IPOs and venture capital The new issue market and raising funds through initial public offering (IPO) Advantages and disadvantages of ‘going public’ for the biotech start-up Pros and cons of private placements Venture capital financing Trends in venture capital financing in the US and Europe Qualitative and quantitative analyses of venture capital funding trends Advantages and disadvantages Stephanie Léouzon, Managing Director, Credit Suisse First Boston COMMERCIALISING A DRUG-DISCOVERY PROCESS IN ANTI-INFECTIVE RESEARCH 10.20 The crucial factors World leading science Strong management Clear business model Broad product portfolio Supportive investors Ken Powell, Chief Executive Officer, Arrow Therapeutics 11.00 Morning Coffee RISK MANAGEMENT AND BARRIERS TO COMMERCIALISATION 11.20 What can be done to minimise risks and overcome barriers? Does biotechnology involve such high-risks? Understanding barriers Understanding risks Strategies to overcome barriers and manage risks Developing a successful commercialisation strategy acknowledging risk and barriers Dr Stephen Castle, Managing Director, Mattson Jack Group-Europe M&A AS A STRATEGY FOR COMMERCIALISATION 12.00 Considerations of scale and attractiveness to capital markets influence current M&A thinking Facing the harsh imperative of M&A Ambitious business models required for a new era Acquisition of critical mass Diversification of development risk Capabilities versus cash Maximising valuation and providing liquidity options to shareholders Geoff Collett, Vice President, Corporate Development, Lorus Therapeutics 12.40 Networking Lunch THE IMPACT OF PHARMACOGENOMICS ON DRUG DISCOVERY, DEVELOPMENT AND COMMERCIALISATION 2.00 Transforming potential into value Overcoming ‘pharmacogenomicsophobia’ Attuning drug development to genetic variability Targeting blockbusters and eliminating non-responders Making pharmacogenomics happen Changing the diagnostics paradigm Healthcare impact Dr Bruce L Maloff, Executive Vice President, Commercial Operations, Variagenics IMPLEMENTING DECISION ANALYSIS IN THE PHARMACEUTICAL ARENA 2.40 Making high quality decisions for drug development A brief history of decision analysis (DA) and its application to R&D intensive enterprises A review of the application of DA to problems in pharmaceutical development How to assess development risk, commercial return and produce high quality decisions Case study: How DA was implemented at Abbott How Abbott uses DA in pharma development Dr Steven Kuemmerle, Director, Decision Support Group, Abbott Laboratories 3.20 Afternoon Tea TECHNOLOGY MANAGEMENT 3.40 A new paradigm Pharmaceutical market consolidation The needs of academia The MMI model Strategic alliances The investor’s view David Best, Chairman, Medical Marketing International Group 4.20 STRATEGIES, NEED AND IMPACT OF HIGH QUALITY COMBINATORIAL CHEMISTRY ON DRUG DISCOVERY CAPABILITIES OF THE PHARMACEUTICAL INDUSTRY IN THE POST-GENOMICS ERA Augment the internal drug discovery capabilities of pharmaceutical and biopharmaceutical companies Broaden and deepen our technology through internal inventions, acquisitions, multiple revenue streams and expand our knowledge base Understand what business partners want A clear pathway from research ideas to high quality products Fully integrated chemistry platform Good combinatorial libraries come from good science Dr Kumar G Gadamasetti, Senior Director, ChemRx Advanced Technologies [Discovery Partners International] 5.00 Chairman's Closing Remarks and Close of Conference Workshop MANAGING UNCERTAINTY In association with Mattson Jack Group-Europe 23rd May 2001 This workshop builds on many of the aspects covered in the preceding conference. Forecast models and valuations are essential in today’s process of commercialisation. A good forecast model will capture the essential elements of the product and market – as it is seen today and how it is perceived to develop over time - taking into consideration changes in the environment at a macro and micro level. Understanding the essential elements enables the practitioner to start managing uncertainty. This workshop will focus on lessons learnt from over 20 years of technology and product assessments, captured in forecast models – presenting best practice in managing uncertainty. Case studies will be used throughout the workshop - including Monte Carlo analysis, NPV and P&L, epidemiology (research & analysis) and means of generating data to support assumptions via primary and secondary market research. 8.30 Registration and coffee 9.00 Purpose and output of forecasts Best practice in forecasting Methods and tools in forecasting 11.00 Morning coffee 11.15 Epidemiology – patient based forecasting Generating and supporting assumptions Managing uncertainty 12.30 Discussion and review of session 1.00 Close of session About your workshop leaders Nic Talbot-Jenkins joined MJG in 1998 as Senior Analyst and is responsible for forecast modelling for the Group. She has worked on the assessment of many therapy sectors and technologies from early to late stage technology. Julie Davidson is a qualified epidemiologist trained in both the UK and USA and she is responsible for supporting companies in identifying relevant patient populations. Stephen Castle has 15 years biotech/pharma industry experience primarily in sales, marketing and business development with in-depth exposure to understanding and managing uncertainty. |
||||||||||||||||
| Organized by: | Katherine Britton, Deputy Head of Pharma Conferences, SMi | |||||||||||||||
| Invited Speakers: | Dimitri F Dimitriou, Senior Director, Worldwide Business Development, GlaxoSmithKline Dr Steve Kuemmerle, Director, Decision Support Group, Abbott Laboratories Dr John Brown, Chief Executive Officer, Acambis Adam Raman, Director, Strategy Development, PHASE II International Prof Howard Stevens, Pfizer Professor of Exploratory Drug Delivery, Department of Pharmaceutical Sciences, University of Strathclyde Ken Powell, Chief Executive Officer, Arrow Therapeutics Cynthia Larbey, Managing Director, People in Health Geoff Collett, Vice President, Corporate Development, Lorus Therapeutics David Best, Chairman, Medical Marketing International Group Dr Bruce L Maloff, Executive Vice President, Commercial Operations, Variagenics Dr Elma S Hawkins, Vice Chairman, Antigenics Dr Kumar G Gadamasetti, Senior Director, ChemRx Advanced Technologies [Discovery Partners International] Mark A King, Managing Director, Kendall Strategies Glynn Edwards, Chief Executive Officer, Antisoma Dr Stephen Castle, Managing Director, Mattson Jack Group-Europe Stephanie Léouzon, Managing Director, Credit Suisse First Boston Antony Ross, Director of Healthcare, 3I Dr Peter MacLennan, Director of Business Development, Ark Therapeutics Chaired by: Dimitri F Dimitriou, Senior Director, Worldwide Business Development, GlaxoSmithKline Dr Nigel Parker, Chief Executive Officer, Ark Therapeutics |
|||||||||||||||
| Deadline for Abstracts: | Programme is now full, please come along as a delegate | |||||||||||||||
| Registration: | Register on-line at www.smi-online.co.uk/commercial.asp or phone for a brochure +44 (0) 20 7827 6048 On-the-day registrations welcome. Price: £1298 Conference plus workshop, £999 conference only, £399 workshop only. 50% Discount for academics and charities |
|||||||||||||||
| E-mail: | kbritton@smi-online.co.uk | |||||||||||||||
| Posted by: | Katherine Britton | |||||||||||||||
| Host: | 213.38.112.46 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||